Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 23;5(4):e000823. doi: 10.1136/esmoopen-2020-000823

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CD47 expression and tumour-associated macrophage infiltration. (A) Representative IHC images of different CD47 expression level scores in tumour and lung tissue (control respiratory disease sample). (B) CD47^pos expression in NSCLC is higher than in the control group (infection lung tissues) (33.0% vs 17.4%, p=0.038). (C) Tumour CD47^pos expression in female patients with NSCLC was higher than in male patients with NSCLC (43.5% vs 27.0%, p=0.020). (D) Tumour CD47^pos expression in never-smokers with NSCLC was higher than in smokers with NSCLC (46.1% vs 21.6%, p<0.001). (E) Tumour CD47^pos expression in LUAD was higher than in LUSC (52.0% vs 12.9%, p<0.001). (F) Representative immunofluorescence images of CD68^pos macrophages, CD163^pos macrophages, M2-TAMs (CD8^pos, CD163^pos) and M1-TAMs (CD68^pos, CD163^neg). (G) High M2/M1 ratios were more frequently observed in NSCLC compared with the control group (71.7% vs 45.7%, p=0.001). (H) M2 infiltration in the tumour area was higher than M1 infiltration in the tumour area (89 vs 57, p=0.001). (I) M2 infiltration in the tumour area in stage III NSCLC was higher than in stage I NSCLC (64.2% vs 29.2%, p<0.001). (J) High M2/M1 ratios were more frequently observed in stage III NSCLC than in stage I NSCLC (83.1% vs 57.3%, p<0.001). *p<0.05, **p<0.001. CD47^pos, cases with CD47 IHC scores of 2+ or 3+ were considered positive for tumour CD47 positive expression; CD47^neg, cases with CD47 IHC scores of 1+ or ve (0) were considered negative for tumour CD47 expression; if, immunofluorescence; IHC, immunohistochemistry; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non-small cell lung cancer; NT, non-tumour area; TAMs, tumour-associated macrophages; T&NT, tumour area and non-tumour area.